Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Reiterated by HC Wainwright

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $10.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 491.72% from the stock’s current price.

Separately, StockNews.com raised shares of Lexicon Pharmaceuticals to a “sell” rating in a research note on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $7.50.

Lexicon Pharmaceuticals Trading Up 5.0 %

LXRX opened at $1.69 on Thursday. The stock has a 50-day moving average of $1.70 and a 200 day moving average of $1.81. The company has a current ratio of 11.51, a quick ratio of 11.49 and a debt-to-equity ratio of 0.41. Lexicon Pharmaceuticals has a 12 month low of $0.92 and a 12 month high of $3.73. The firm has a market cap of $416.14 million, a P/E ratio of -2.04 and a beta of 1.28.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. Lexicon Pharmaceuticals had a negative return on equity of 105.38% and a negative net margin of 5,509.34%. The firm had revenue of $1.65 million during the quarter, compared to analysts’ expectations of $2.74 million. During the same quarter in the previous year, the business earned ($0.22) EPS. As a group, research analysts forecast that Lexicon Pharmaceuticals will post -0.69 EPS for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC raised its position in Lexicon Pharmaceuticals by 107.6% during the 3rd quarter. SG Americas Securities LLC now owns 46,090 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 23,893 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in shares of Lexicon Pharmaceuticals during the second quarter valued at $3,871,000. Point72 Asset Management L.P. raised its holdings in shares of Lexicon Pharmaceuticals by 605.2% in the second quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock valued at $6,924,000 after acquiring an additional 3,536,805 shares in the last quarter. CVI Holdings LLC purchased a new stake in Lexicon Pharmaceuticals in the second quarter worth about $34,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Lexicon Pharmaceuticals by 40.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 49,957 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 14,411 shares in the last quarter. 74.70% of the stock is owned by hedge funds and other institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.